Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD1-PSMA-CART
- Development stage
- Phase 1
- Lead developer
- BRL Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PD1-PSMA-CART is an experimental, autologous CAR-T cell therapy in which patient T cells are genetically engineered to express a chimeric antigen receptor (CAR) targeting prostate-specific membrane antigen (PSMA) and are further modified for intrinsic PD-1 blockade. This is achieved through non-viral gene integration, resulting in T cells that both target PSMA-expressing prostate cancer cells and circumvent PD-1-mediated immunosuppression commonly found in the tumor microenvironment. Its mechanism involves direct immunological cytotoxicity to PSMA+ tumor cells and interruption of the PD-1 checkpoint pathway. The primary indication being investigated is refractory castrate-resistant prostate cancer. The therapy is developed by BRL Medicine Inc and clinical evaluation is sponsored by Zhejiang University[4][5].
- Other names
- PD1-PSMA-CART cellsPD-1-PSMA-CART cellsPD 1-PSMA-CART cells
02
Targets
PSMA (Prostate-specific membrane antigen)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PD1-PSMA-CART.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD1-PSMA-CART.